Objective: Previous studies have demonstrated that visual analog scales (VASs) are valid and reliable instruments for measuring the severity of premenstrual symptoms. Most of these studies, though, predate the introduction of DSM-IV diagnostic criteria for premenstrual dysphoric disorder (PMDD). Our objective was to assess the reliability and validity of VASs that were revised to better reflect the DSM-IV definition of PMDD.
T he diagnostic criteria for premenstrual dysphoric disorder (PMDD), as defined in the DSM-IV, are much stricter than those for premenstrual syndrome (PMS) (1) . To apply the DSM-IV criteria for PMDD, women must prospectively chart symptoms daily for at least 2 consecutive symptomatic cycles, and their chief complaints must include 1 of the 4 core mood symptoms (that is, irritability, tension, dysphoria, and lability of mood) and at least 5 of the 11 total symptoms. The charting of symptoms should clearly demonstrate premenstrual worsening and remission within a few days after the onset of menstruation ("on-offness") (2) . A change in symptoms from the follicular to the luteal phase of at least 50% is suggested for the diagnosis of PMDD (3, 4) .
Results from a study of women with PMS who sought medical attention suggest that the DSM-IV criteria for PMDD may be too strict (5) . Subjects failing to meet the criteria may still have substantial premenstrual worsening of symptoms. Prospective daily self-rating of symptoms, using reliable and valid instruments, is essential in making the diagnosis. To date, there is still no consensus among investigators as to the best instrument for confirming prospectively the diagnosis of PMDD, nor is there consensus as to the most appropriate instrument to measure treatment effects in clinical trials (6) .
Previous studies have shown that using a single-item visual analog scale (VAS) for each of the 4 core premenstrual mood symptoms is a reliable and valid method of prospective data collection (3, 4) . Most of these studies, though, predate the introduction of the DSM-IV diagnostic criteria for PMDD, and previous VASs are not aligned with these criteria. We further report here on the reliability and validity of the VASs that were revised to better reflect the DSM-IV definition of PMDD.
Methods
The analysis used concurrent data from women's scores on the revised VASs and the validated Premenstrual Tension Syndrome Observer (PMTS-O) rating scale collected in 4 randomized controlled trials (n = 1208) evaluating the efficacy of different treatment options with paroxetine. In all these trials, women with premenstrual symptoms that fulfilled the DSM-IV diagnostic criteria for PMDD signed a written informed consent form that was approved by the institutional review board at participating centres.
The validated PMTS-O scale allows an observer to assess symptoms in 10 domains: irritability or hostility, tension, efficiency, dysphoria or moodiness, motor coordination, mental-cognitive functioning, eating habits, sexual drive and activity, physical symptoms, and social impairment (7) . VASs, together with the PMTS-O scale, have been shown to be a valid, reliable, and sensitive measure for the severity of premenstrual symptoms (3). The PMTS-O scale has also been used in subjects with premenstrual symptoms to establish symptom severity for inclusion in clinical studies (8) (9) (10) (11) and to evaluate treatment response in clinical trials (12) (13) (14) (15) .
In 3 trials with regular visits scheduled during the follicular phases (that is, each within 3 days after onset of menses), 1030 participants were randomized to treatment groups of continuous treatment with paroxetine (12.5 mg daily), paroxetine (25 mg daily), or placebo (16) . The trials were conducted according to an identical protocol with minor language adaptations for different geographic regions of Europe and North America. Participants completed a self-rating set of 11 VASs daily throughout 6 menstrual cycles (2 screening, 1 baseline, and 3 treatment cycles). Single-item VASs were used to measure each of the 4 core mood symptoms (depressed mood, tension, affective lability, and irritability), as well as the 7 additional clusters of symptoms (decreased interest in usual activities, difficulty with concentration, lack of energy, change in appetite, change in sleep pattern, feeling out of control, and physical symptoms), in accordance with the DSM-IV criteria for PMDD (1) . During regular visits, independent observers also assessed participants by using a retrospective data collection approach with the PMTS-O scale, prompting for the severity of premenstrual symptoms associated with the late luteal phase of the preceding menstrual cycles.
In one trial with regular visits scheduled during the luteal phases, 178 participants were randomized to treatment groups receiving continuous treatment with paroxetine (20 mg daily), intermittent treatment with paroxetine (20 mg daily during the luteal phase only), or placebo (17) . Participants completed a self-rating, slightly modified (that is, a Swedish version) set of 10 VASs daily for 6 cycles. Single-item VASs were used to measure each of the 4 core mood symptoms (depressed mood, tension, affective lability, and irritability) as well as 6 additional clusters of symptoms (mood swings, bloatedness, breast tenderness, lack of energy, food cravings, and menstrual pain). A single observer used a prospective data collection approach with the PMTS-O scale to assess participants during their luteal phases.
In all trials, each VAS consisted of a 100-mm horizontal line with vertical line anchors at each end. The anchors were 0 = "not at all" (that is, "the way you normally feel when you don't have premenstrual symptoms") and 100 = "extreme symptoms" (that is, "the way you feel when your premenstrual symptoms are at their worst").
Data Analysis
All analyses were based on intention-to-treat. For the analyses, data from the 3 trials with follicular phase visits were pooled on the basis of their identical protocols and the homogeneous results from the reliability analyses of individual trial data. Data from the trial with luteal phase visits were analyzed separately.
The VAS scores on the 4 core symptoms were averaged to create a mean score to represent mood symptoms (that is, VAS mood score) (4). We calculated the VAS total scores (average of 11 symptom scores) only for the trials with follicular phase visits. For the trial with luteal phase visits, the VAS total scores (average of 10 symptom scores) were not derived because they were not comparable with those derived from the other trials. We calculated a late luteal phase score (that is, VAS mood or VAS total), using the average daily VAS scores of the 5 days prior to menses, and a follicular phase score, using the average of daily VAS scores from postmenses days 6 to 10.
The PMTS-O scale scores 10 domains (outlined above) with severity ranging from 0 to 4 in 8 subscales and 0 to 2 in 2 domains, for a maximum score of 36. A PMTS-O mood subscore includes items from question 1 (irritability or hostility), question 2 (tension), and question 4 (dysphoria or moodiness) and ranges from 0 to 12.
Change scores from both VAS and PMTS-O scales were used to assess sensitivity to symptom worsening or improvement. A change score was derived by subtracting a baseline score from the corresponding score at study end (that is, the third treatment cycle in all trials). For participants who dropped out, we used the score of the last cycle before early termination.
Cronbach's alpha coefficient was used at baseline to evaluate the internal consistency of the VAS mood items. Baseline VAS scores were summarized for the late luteal and follicular phases across treatment options. To evaluate construct validity, we compared VAS mood scores for subgroups of participants with varying premenstrual symptom severity according to a priori defined PMTS-O thresholds. A PMTS-O total score greater than 27 has been suggested for severe symptoms, between 18 and 27 for moderate symptoms, and between 10 and 17 for mild symptoms (18, 19) . Analysis of variance was used to compare subgroups.
Pearson's correlation was used to compare the DSM-IV VAS and PMTS-O scores. Both absolute scores at baseline and change scores were compared. Individual items, mood domain scores, and total scores were compared.
To examine the construct validity of the VAS items relative to those of the PMTS-O scale, pairwise correlation coefficients were examined between the 4 core mood symptoms in the VAS scale and the corresponding 3 symptoms from the PMTS-O scale. Correlation coefficients from 0.3 to 0.5 indicated moderate association; from 0.5 to 0.7, strong association; and above 0.7, excellent association (20) .
Results
Data from 1208 participants were used in the analyses. In the trials with follicular phase visits, 1030 participants contributed data to the baseline analyses and 934 (88%) to the change 
Total score 23 (5) 22 (5) 22 (5) 22 (5) 21 (5) 19 (4) a VAS mood score is the average of the 4 core mood symptoms (that is, depressed mood, tension, affective lability, and irritability) according to DSM-IV definition of PMDD. VAS total score is the average from the VAS score of 11 symptoms according to DSM-IV definition of PMDD.
score analyses. For the trial with luteal phase visits, the corresponding figures were 178 and 165 (93%), respectively (Tables 1 and 2 ).
The internal consistency coefficient for the luteal VAS mood score was 0.90 with data from the 3 trials with follicular phase visits (ranging from 0.90 to 0.91 across trials) and 0.88 with data from the trial with luteal phase visits. The corresponding coefficients for the follicular VAS mood score were 0.94 (ranging from 0.92 to 0.96 across trials) and 0.91, respectively. These results indicate a high level of internal consistency among the 4 core mood symptoms.
The VAS mood scores captured the "on-offness" of the conditions, with the mean VAS mood score ranging from 47 to 57 across treatment options for the late luteal phase and from 5 to 9 for the subsequent follicular phase. Similar results were observed with the VAS total scores (Table 1) .
According to the construct validity criterion, 15% (n = 153) of participants in the trials with follicular phase visits experienced mild premenstrual symptoms; 68% (n = 682), moderate symptoms; and 17% (n = 171), severe symptoms. The mean VAS mood score was 41 (95%CI, 38 to 44) for participants with mild symptoms, 54 (95%CI, 52 to 55) for those with moderate symptoms, and 70 (95%CI, 66 to 73) for those with severe symptoms. The mean VAS mood score was significantly different across symptom severities (F 2,1003 = 75.7, P < 0.0001).
Luteal phase VAS scores and corresponding PMTS-O scores were moderately correlated at baseline (P < 0.01) ( Table 2 ).
The correlation coefficient between VAS mood and PMTS-O mood scores was 0.48 for the 3 trials with follicular phase visits (ranging from 0.42 to 0.50 across individual trials) and 0.46 for the trial with luteal phase visits. Luteal phase VAS change scores and corresponding PMTS-O change scores were strongly correlated (P < 0.01), indicating similar sensitivity to premenstrual symptom change by both scales. Whether observers assessed symptom severity retrospectively or prospectively, the correlations between the patient-reported VAS scores and the PMTS-O scores were comparable (Table 2) . Corresponding items from the 2 scales (for example, VAS depressed mood and PMTS-O dysphoria or moodiness) always attained relatively higher correlation values when compared with correlation between noncorresponding items (for example, VAS depressed mood and PMTS-O tension), suggesting further evidence of the construct validity of VAS items.
Discussion
Data collected from 4 treatment trials of women with severe premenstrual symptoms indicate that using the revised VASs (which better reflect the current DSM-IV definition of PMDD) provides a reliable measure of premenstrual symptoms when evaluated against the well-validated PMTS-O scale. The results also suggest similar concurrent validity between the daily rating of symptom severity using the patient-reported revised VAS and the observers' rating scale (PMTS-O), regardless of whether the observers assessed the Change scores from baseline to trial end (that is, baseline score -end of treatment score).
NA = not available (VAS total scores from the trial with luteal phase visits were not comparable with those from the 3 trials with follicular visits.)
premenstrual symptoms with a prospective or retrospective data collection approach.
The DSM-IV requires women to prospectively chart symptoms daily for a minimum of 2 symptomatic cycles to qualify for the diagnosis of PMDD and hence meet inclusion criteria in clinical trials. It has recently been suggested that this may be impractical as a diagnostic tool in a busy primary care practice. Not only has it been shown that the requirement for prospective charting may act as a deterrent for seeking help, it may also indicate that patients who participate in clinical trials are very different from typical PMDD patients seen in primary care (21) .
The revised VAS better reflects the current DSM-IV diagnostic criteria for PMDD, and it is also more user-friendly. As such, it can potentially increase the accurate identification of sufferers and also improve their compliance with treatment.
Most women with severe PMS or PMDD are likely to seek treatment from their obstetrician-gynecologist or other primary health care provider. At present, there is still no consensus on diagnostic criteria for severe PMS and PMDD (22) . Recent attempts at circumventing the need for a prospective daily paper and pencil charting are promising (23, 24) ; however, further validation studies are needed. The data presented here seem to also indicate that, in women with clear-cut severe PMS and (or) PMDD, retrospective assessment may be a clinically acceptable alternative to strict DSM-IV research diagnostic criteria. Méthodes : L'information concurrente de l'échelle de mesure bien validée de l'observateur du syndrome de tension prémenstruelle (PMTS-O) a servi à évaluer les EVA révisées. Les données de 4 essais contrôlés randomisés (n = 1 208) évaluant l'efficacité de la paroxétine pour le traitement du TDPM ont été utilisées. Le coefficient alpha de Cronback a servi à évaluer la cohésion interne des principaux items sur l'humeur des EVA. La corrélation de Pearson entre les scores aux 2 échelles a servi à évaluer la fiabilité.
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Résultats : La cohésion interne des principaux items sur l'humeur des EVA (alpha de Cronback > 0,90 dans tous les essais) était élevée. Les scores lutéaux aux EVA et les scores correspondants à la PMTS-O étaient modérément corrélés à la base (P < 0,01). Les scores de changement lutéaux aux EVA et les scores de changement correspondants à la PMTS-O étaient fortement corrélés (P < 0,01). Ces résultats ne différaient pas, que les données de la PMTS-O soient recueillies prospectivement ou rétrospectivement.
Conclusion :
Les EVA révisées, qui s'approchent de la définition actuelle du TDPM du DSM-IV, offrent une mesure valide et fiable de la gravité des symptômes prémenstruels, quand elles sont évaluées par rapport à l'échelle PMTS-O validée. Nos résultats suggèrent également que les corrélations avec les scores aux EVA déclarés par les patients étaient comparables, que les observateurs aient évalué la gravité du TDPM prospectivement ou rétrospectivement.
